SCHEDULE 13G/A: T. Rowe Price Boosts Hologic Stake to 9.7%

T. Rowe Price Investment Management, Inc. has disclosed an updated beneficial ownership of 9.7% in Hologic Inc., holding over 21.5 million common shares.

Summary

• T. Rowe Price Investment Management, Inc. reported beneficial ownership of 21,550,364 shares of Hologic Inc. common stock.
• This represents 9.7% of the class of securities.
• The filing is an Amendment No. 4 to a Schedule 13G.
• T. Rowe Price holds sole voting power over 21,306,933 shares and sole dispositive power over 21,549,648 shares.
• The reporting person is classified as an Investment Adviser, based in Maryland.

Sentiment

Score: 5

Explanation: Neutral. This is a factual disclosure of institutional ownership, not an announcement of company performance or strategic changes. It reflects T. Rowe Price's continued significant stake in Hologic Inc.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Hologic Inc. or T. Rowe Price Investment Management, Inc. regarding the issuer's future performance.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.
• By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates continued significant institutional interest in Hologic Inc., a company operating in the medical technology and diagnostics sector. Large institutional holdings like this are common for established companies in the healthcare industry, reflecting a long-term investment perspective.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional holding by T. Rowe Price may provide a degree of confidence regarding the stock's long-term prospects, as it indicates a major investment firm maintains a substantial position.
• Company Management: Awareness of a large, passive institutional holder like T. Rowe Price can influence management's strategic decisions, though the filing explicitly states the shares are not held for control purposes.

Key Dates

Keywords

Hologic Inc, Hologic, T. Rowe Price, Investment Management, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Medical Technology, Diagnostics